Connect Biopharma (NASDAQ:CNTB) Announces Earnings Results, Misses Expectations By $0.05 EPS

Connect Biopharma (NASDAQ:CNTB) issued its quarterly earnings results on Tuesday. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.05), Zacks reports. The business had revenue of $0.02 million during the quarter.

Connect Biopharma Trading Up 2.0%

CNTB traded up $0.05 during trading on Thursday, hitting $2.50. 104,275 shares of the stock were exchanged, compared to its average volume of 198,316. The firm has a 50 day simple moving average of $2.74 and a 200 day simple moving average of $2.51. The firm has a market cap of $141.24 million, a price-to-earnings ratio of -2.17 and a beta of -0.21. Connect Biopharma has a 1 year low of $0.70 and a 1 year high of $3.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 3.74.

Insider Buying and Selling

In related news, Director James Huang purchased 1,160,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were acquired at an average cost of $3.45 per share, for a total transaction of $4,002,000.00. Following the acquisition, the director owned 13,160,000 shares of the company’s stock, valued at $45,402,000. The trade was a 9.67% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC acquired a new stake in shares of Connect Biopharma in the 4th quarter worth $36,000. HRT Financial LP boosted its position in shares of Connect Biopharma by 60.5% in the 4th quarter. HRT Financial LP now owns 16,785 shares of the company’s stock worth $47,000 after purchasing an additional 6,328 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Connect Biopharma in the 4th quarter worth $76,000. XTX Topco Ltd acquired a new stake in shares of Connect Biopharma in the 2nd quarter worth $29,000. Finally, Royal Bank of Canada acquired a new stake in shares of Connect Biopharma in the 4th quarter worth $114,000. 58.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CNTB shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Connect Biopharma in a research note on Monday, May 4th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Connect Biopharma in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.67.

Trending Headlines about Connect Biopharma

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 earnings estimate for Connect Biopharma, suggesting a slightly better outlook for that period. Source article
• Neutral Sentiment: Connect Biopharma said management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, which keeps the company visible to biotech investors but is not a major operational catalyst. Source article
• Neutral Sentiment: The company also announced it will present at an upcoming investor conference, which may support trading interest but does not change fundamentals on its own. Source article
• Negative Sentiment: HC Wainwright lowered its Q2, Q3, FY2026, FY2027, FY2028, FY2029, and FY2030 EPS estimates, reflecting a softer long-term earnings outlook for Connect Biopharma. Source article
• Negative Sentiment: Connect Biopharma’s latest quarterly results missed expectations, with EPS of -$0.34 versus the -$0.29 consensus and only $0.02 million in revenue, which can weigh on sentiment. Source article

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.